PERCEPTIVE INFORMATICS ANNOUNCES RELEASE OF WEB-BASED IMPACT
BOSTON, MA, March 2, 2004 — Perceptive Informatics, Inc., a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), and a provider of innovative technology-based solutions designed to accelerate drug development, today announced the launch of a web-based version of IMPACT, Perceptive’s leading clinical trials management system (CTMS). Web-based IMPACT delivers additional functionality and provides online accessibility to critical trial management data enabling bio/pharmaceutical companies and clinical research organizations to better administer the complex process of conducting clinical trials. The web-based version also offers an improved and intuitive user interface and navigation capability that enhances the overall usability of the system.
IMPACT represents the core of a broader suite of clinical trial management applications referred to as IMPACT Clinical Systems. The integrated application modules include Clinical Cost Tracking, Clinical Supplies Tracking, CRO Monitoring Portal and INVESTIGATOR, a leading investigator database solution. In addition, IMPACT has been integrated with Perceptive Voice™, the Company’s interactive voice response system (IVRS), to provide automatic real-time data transfer.
"Currently used by over half of the top 20 pharmaceutical companies and with over 14,000 users worldwide, IMPACT is a CTMS market leader," said Mark A. Goldberg, MD, President of Perceptive Informatics, Inc. "Its enhanced functionality and online accessibility enable IMPACT Clinical Systems to surpass the traditional limits of clinical trials management systems. In addition, the integration and availability of the web-based system demonstrates the commitment of Perceptive Informatics to be a driving force in providing solutions for enhanced clinical trials management."
Perceptive Informatics, Inc. develops and offers a portfolio of innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions and tracking tools, Interactive Voice Response Systems (IVRS), and clinical trial management systems (CTMS). IMPACT is Perceptive's market leading CTMS product and INITIATOR is a trial management product targeted to the needs of Phase I units. Perceptive offers advanced medical imaging services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. In addition, the company provides electronic diary and investigator database solutions. Perceptive is headquartered near Boston, MA with approximately 300 employees in offices located throughout North America and Europe. Perceptive Informatics is a subsidiary of PAREXEL International Corporation.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears", "estimates", "projects" and similar expressions are intended to identify forward-looking statements. These statements involve a number of risks and uncertainties. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry; competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2003 as filed with the SEC on February 10, 2004, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent PAREXEL’s estimates as of the date of this release. PAREXEL specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL’s estimates or views as of any date subsequent to the date of this press release.